Technical Analysis for TEVA - Teva Pharmaceutical Industries

Grade Last Price % Change Price Change
grade B 13.19 -0.90% -0.12
TEVA closed down 0.9 percent on Friday, February 21, 2020, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical TEVA trend table...

Date Alert Name Type % Chg
Boomer Buy Setup Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Calm After Storm Range Contraction -0.90%
NR7 Range Contraction -0.90%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. It offers generic pharmaceutical products; and basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances. The company's principal branded pharmaceutical products comprise Copaxone for multiple sclerosis; Provigil and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Azilect for the treatment of Parkinson's disease; Fentora and Actiq for the treatment of pain in opioid-tolerant adult patients with cancer; Amrix for muscle spasm in acute, painful, and musculoskeletal conditions; ProAir for the treatment of bronchial spasms; Qvar for long-term control of chronic bronchial asthma; and Qnasl Nasal Aerosol for seasonal nasal and year-round nasal allergy symptoms. The company also offers Treanda for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma; Tevagrastim/Ratiograstim that stimulate the production of white blood cells; Eporatio, which stimulates the production of red blood cells; Synribo for chronic myeloid leukemia; Plan B One-Step for emergency oral contraception; ParaGard, a non hormonal intrauterine contraceptive; hormone therapies for menopause/perimenopause; Enjuvia for vasomotor symptoms associated with menopause; and therapies for infertility and urinary incontinence. In addition, it produces active pharmaceutical ingredients in the areas of respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company distributes third party products. It has collaborative agreements with Lonza Group Ltd. and OncoGenex Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Medicine Chemistry Cancer Pharmaceutical Pain Drugs Medication Pharmaceutical Products Multiple Sclerosis Parkinson's Disease Lymphoma Active Pharmaceutical Ingredients Asthma Leukemia Chronic Lymphocytic Leukemia Treatment Of Parkinson's Disease Obstructive Sleep Apnea Fentanyl Generic Pharmaceutical Products Muscle Spasm Party Products Treatment Of Chronic Lymphocytic Leukemia Urinary Incontinence Chronic Myeloid Leukemia Infertility Menopause Narcolepsy Teva Pharmaceutical Industries

Is TEVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.61
52 Week Low 6.07
Average Volume 17,627,632
200-Day Moving Average 9.08
50-Day Moving Average 10.58
20-Day Moving Average 11.81
10-Day Moving Average 12.74
Average True Range 0.62
ADX 32.7
+DI 38.03
-DI 17.06
Chandelier Exit (Long, 3 ATRs ) 11.91
Chandelier Exit (Short, 3 ATRs ) 11.39
Upper Bollinger Band 14.13
Lower Bollinger Band 9.48
Percent B (%b) 0.8
BandWidth 39.36
MACD Line 0.80
MACD Signal Line 0.71
MACD Histogram 0.0929
Fundamentals Value
Market Cap 13.4 Billion
Num Shares 1.02 Billion
EPS -6.11
Price-to-Earnings (P/E) Ratio -2.16
Price-to-Sales 0.60
Price-to-Book 0.57
PEG Ratio -0.47
Dividend 1.10
Dividend Yield 8.34%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.61
Resistance 3 (R3) 13.61 13.46 13.54
Resistance 2 (R2) 13.46 13.36 13.47 13.52
Resistance 1 (R1) 13.33 13.29 13.40 13.33 13.49
Pivot Point 13.18 13.18 13.22 13.19 13.18
Support 1 (S1) 13.05 13.08 13.12 13.05 12.89
Support 2 (S2) 12.90 13.01 12.91 12.86
Support 3 (S3) 12.77 12.90 12.84
Support 4 (S4) 12.77